Published on GHDx (https://ghdx.healthdata.org)

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

General Info

Geography 
Global
Coverage type 
Global
Time period covered 
January, 2022 - December, 2022
Data type
Scientific literature
Keywords 
Colon and rectum cancers

Citation

Authors 
Diaz LA Jr, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fourchardiere C, Rivera F, Elez E, Le DT, Yoshino T, Zhong WY, Fogelman D, Marinello P, Andre T, KEYNOTE-177 Investigators
Journal 
Lancet Oncol
Pages 
659-670
Publication year 
2022
Suggested citation 
Diaz LA Jr, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fourchardiere C, Rivera F, Elez E, Le DT, Yoshino T, Zhong WY, Fogelman D, Marinello P, Andre T, KEYNOTE-177 Investigators. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022; 23(5): 659-670.
Source URL:https://ghdx.healthdata.org/record/pembrolizumab-versus-chemotherapy-microsatellite-instability-high-or-mismatch-repair#comment-0